drugset / Trial / NCT04545151

Verapamil SR in Adults With Type 1 Diabetes

NCT04545151

RandomizedParallel-groupDouble-blindTreatment

Summary

This study has been set up within the framework of the INNODIA network. INNODIA is a global partnership between 31 academic institutions, 6 industrial partners, a small sized enterprise and 2 patient organizations, bringing their knowledge and experience together with one common goal: "To fight type 1 diabetes". (www.innodia.eu) The overall aim of INNODIA is to advance in a decisive way how to predict, stage, evaluate and prevent the onset and progression of type 1 diabetes (T1D). For this, INNODIA has established a comprehensive and interdisciplinary network of clinical and basic scientists, who are leading experts in the field of T1D research in Europe and UK (United Kingdom), with complementary expertise from the areas of immunology, Beta-cell biology, biomarker research and T1D therapy, joining forces in a coordinated fashion with industry partners and two foundations, as well as with all major stakeholders in the process, including regulatory bodies and patients with T1D and their families.

Timeline

Start
2021-02-08
Primary completion
2025-04-23
Completion
2026-04-17

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Verapamil Other / unclassified 360 mg Oral